CA2932077C - Methode pour diagnostiquer des troubles associes a une lesion cerebrale - Google Patents

Methode pour diagnostiquer des troubles associes a une lesion cerebrale Download PDF

Info

Publication number
CA2932077C
CA2932077C CA2932077A CA2932077A CA2932077C CA 2932077 C CA2932077 C CA 2932077C CA 2932077 A CA2932077 A CA 2932077A CA 2932077 A CA2932077 A CA 2932077A CA 2932077 C CA2932077 C CA 2932077C
Authority
CA
Canada
Prior art keywords
protein
gfap
fabp
mutant
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2932077A
Other languages
English (en)
Other versions
CA2932077A1 (fr
Inventor
Denis Francois Hochstrasser
Jean Charles Sanchez
Pierre Lescuyer
Laure Allard
Original Assignee
Electrophoretics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0419068A external-priority patent/GB0419068D0/en
Application filed by Electrophoretics Ltd filed Critical Electrophoretics Ltd
Priority claimed from CA2532130A external-priority patent/CA2532130C/fr
Publication of CA2932077A1 publication Critical patent/CA2932077A1/fr
Application granted granted Critical
Publication of CA2932077C publication Critical patent/CA2932077C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Un trouble associé à une liaison cérébrale est diagnostiqué chez un patient par détection dau moins un polypeptide, dune variante ou dun mutant de celui-ci, sélectionné dans le groupe comprenant A-FABP, E-FABP, PGP 9.5, GFAP, la prostaglandine D synthase, la neuromoduline, le neurofilament L, la calcyphosine, une sous-unité de régulation de liaison de lARN, un homologue de la protéine 1 de dégradation de fusion de lubiquitine, la nucléoside diphosphate kinase A, la glutathione S tranférase P, la cathepsine D, la protéine DJ-1, le peroxiredoxine 5 et la peptidyle-prolyle cis-trans isomerase A (cyclophiline A), dans un échantillon de fluide corporel du patient.
CA2932077A 2003-09-20 2004-09-20 Methode pour diagnostiquer des troubles associes a une lesion cerebrale Expired - Lifetime CA2932077C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0322063.9 2003-09-20
GBGB0322063.9A GB0322063D0 (en) 2003-09-20 2003-09-20 Diagnostic method for brain damage-related disorders
GB0414089.3 2004-06-23
GBGB0414089.3A GB0414089D0 (en) 2003-09-20 2004-06-23 Diagnostic method for brain damage-related disorders
GB0419068.2 2004-08-27
GB0419068A GB0419068D0 (en) 2003-09-20 2004-08-27 Diagnostic method for brain damage-related disorders
CA2532130A CA2532130C (fr) 2003-09-20 2004-09-20 Methode pour diagnostiquer des troubles associes a une lesion cerebrale

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2532130A Division CA2532130C (fr) 2003-09-20 2004-09-20 Methode pour diagnostiquer des troubles associes a une lesion cerebrale

Publications (2)

Publication Number Publication Date
CA2932077A1 CA2932077A1 (fr) 2005-03-31
CA2932077C true CA2932077C (fr) 2020-06-02

Family

ID=29266361

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2932077A Expired - Lifetime CA2932077C (fr) 2003-09-20 2004-09-20 Methode pour diagnostiquer des troubles associes a une lesion cerebrale

Country Status (4)

Country Link
CA (1) CA2932077C (fr)
DK (1) DK1664795T3 (fr)
ES (3) ES2657442T3 (fr)
GB (2) GB0322063D0 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009282117B2 (en) * 2008-08-11 2016-05-12 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
CN109696549B (zh) * 2017-10-20 2022-11-01 成都蓝瑙生物技术有限公司 用于脑中风的发光elisa体外诊断试剂盒

Also Published As

Publication number Publication date
ES2657422T3 (es) 2018-03-05
ES2657442T3 (es) 2018-03-05
GB0414089D0 (en) 2004-07-28
GB0322063D0 (en) 2003-10-22
ES2657320T3 (es) 2018-03-02
DK1664795T3 (en) 2018-02-12
CA2932077A1 (fr) 2005-03-31

Similar Documents

Publication Publication Date Title
US7955804B2 (en) Diagnostic method for brain damage-related disorders
JP5281397B2 (ja) 脳損傷関連障害の診断法
JP5775568B2 (ja) 診断方法
US20050272095A1 (en) Methods of identifying biomarkers
DK2389587T3 (en) Diagnostic and prognostic methods related Alzheimer's Disease
EP3242134A1 (fr) Dosage pour le diagnostic d'une maladie neurologique
AU2004264560B2 (en) Method for discriminating between ischemic and haemorrhagic stroke
DK1664795T3 (en) DIAGNOSTIC PROCEDURE FOR Brain Injury-Related Disorders
KR100689995B1 (ko) 알돌라제를 포함하는 망막혈관 질환 진단용 조성물 및 그진단방법
US20140309133A1 (en) Novel Method for Diagnosis of High-Affinity Binders and Marker Sequences
EP4658681A1 (fr) Dosage immunologique par électrochimioluminescence duplex pour a-synucléine totale et ps129-a-synucléine
US20060269963A1 (en) Composition for the diagnosis of retinal vascular disease comprising aldolase and method for diagnosis using it

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160603